Oct 31, 07
|
| NEW STORY |
| 08:00 ET |
King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology
|
|
Jun 02, 06
|
| 08:55 ET |
King Pharmaceuticals Announces Results of Cash Tender Offer for 2-3/4% Convertible Debentures Due November 15, 2021
|
|
May 26, 06
|
| 08:00 ET |
King Pharmaceuticals Announces Extension of Cash Tender Offer for 2-3/4% Convertible Debentures due November 15, 2021
|
|
May 15, 06
|
| 14:56 ET |
King Pharmaceuticals To Present at Bank of America Securities Health Care Conference
|
|
May 09, 06
|
| 07:00 ET |
King Pharmaceuticals Reports First-Quarter 2006 Financial Results
|
|
May 03, 06
|
| 14:16 ET |
King Pharmaceuticals To Webcast Live Conference Call Following Release of First-Quarter 2006 Earnings
|
|
May 02, 06
|
| 11:33 ET |
Correction -- King Pharmaceuticals To Present at Morgan Stanley Global Healthcare Unplugged Conference
|
|
| 08:07 ET |
King Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
|
|
Apr 28, 06
|
| 14:52 ET |
King Pharmaceuticals Announces Cash Tender Offer for 2-3/4% Convertible Debentures Due November 15, 2021
|
|
Apr 25, 06
|
| 11:56 ET |
King Pharmaceuticals Announces Date for Release of First-Quarter 2006 Financial Results
|
|
Mar 24, 06
|
| 13:16 ET |
King Pharmaceuticals Announces Pricing of Convertible Senior Notes Offering
|
|
| 06:00 ET |
King Pharmaceuticals Reports Status of Pediatric Extension for Altace(R)
|
|
Mar 22, 06
|
| 16:18 ET |
King Pharmaceuticals Announces Offering of Convertible Senior Notes
|
|
Mar 02, 06
|
| 07:50 ET |
King Pharmaceuticals Acquires Exclusive Rights to EpiPen(R) In Canada
|
|
Feb 28, 06
|
| 07:03 ET |
King Pharmaceuticals Reports Year-End and Fourth-Quarter 2005 Financial Results
|
|
Feb 27, 06
|
| 18:56 ET |
King Pharmaceuticals Reports Agreement on Dismissal of Altace(R) Patent Litigation
|
|
Feb 23, 06
|
| 16:50 ET |
King Pharmaceuticals Provides Details for Live Webcast and Conference Call Following Release of Fourth Quarter 2005 Earnings
|
|
Feb 21, 06
|
| 17:01 ET |
King Pharmaceuticals Announces Date for Release of Fourth Quarter 2005 Earnings
|
|
Feb 16, 06
|
| 18:11 ET |
King Pharmaceuticals and Arrow International Limited and Affiliates Collaborate on New Formulations of ALTACE(R)
|
|
Feb 08, 06
|
| 08:02 ET |
USAN and WHO Approve Generic Name Bremelanotide for PT-141, First in a New Class of Experimental Treatments for Sexual Dysfunction
|
|
Feb 02, 06
|
| 16:30 ET |
King Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical Conference
|
|
Jan 09, 06
|
| 17:21 ET |
King Pharmaceuticals to Present at JPMorgan Healthcare Conference
|
|
Jan 05, 06
|
| 17:00 ET |
King Pharmaceuticals Commences Phase III Clinical Trial Evaluating Vanquix(R) as a Treatment for Acute, Repetitive Epileptic Seizures
|
|
| 16:30 ET |
King Pharmaceuticals Initiates Phase II Clinical Trial Evaluating MRE0094 as a Treatment for Diabetic Foot Ulcers
|
|
Jan 04, 06
|
| 13:13 ET |
King Pharmaceuticals to Present at Morgan Stanley Pharmaceutical Conference
|
|
Dec 09, 05
|
| 10:59 ET |
King Pharmaceuticals Announces Cross-License Agreement With Mutual Pharmaceutical Company
|
|
Nov 09, 05
|
| 07:01 ET |
King Pharmaceuticals Reports Third-Quarter 2005 Financial Results
|
|
Nov 03, 05
|
| 16:51 ET |
King Pharmaceuticals Provides Details for Live Webcast and Conference Call Following Release of Third-Quarter 2005 Earnings
|
|
Nov 01, 05
|
| 16:07 ET |
King Pharmaceuticals Announces Resolution With Medicaid and Other Governmental Pricing Programs
|
|
Oct 24, 05
|
| 11:22 ET |
King Pharmaceuticals Announces Date for Release of Third-Quarter 2005 Financial Results
|
|
Sep 22, 05
|
| 17:39 ET |
King Pharmaceuticals Reports FDA Acceptance of Altace(R) Supplemental New Drug Application for Delaying the Progression of Chronic Kidney Disease in Hypertensive, Non-Diabetic Patients
|
|
Sep 08, 05
|
| 17:00 ET |
King Pharmaceuticals and Inyx Enter Into Strategic Alliance
|
|
Sep 06, 05
|
| 08:08 ET |
King Pharmaceuticals Reports Publication of HOPE-TOO Clinical Trial Results Showing Sustained Effect of ALTACE(R) in Reducing Risk of Cardiovascular Events
|
|
Aug 09, 05
|
| 07:01 ET |
King Pharmaceuticals Reports Second-Quarter 2005 Financial Results
|
|
Aug 03, 05
|
| 17:38 ET |
King Pharmaceuticals Provides Details for Webcast of Live Conference Call Following Release Of Second-Quarter 2005 Earnings
|
|
Aug 01, 05
|
| 10:10 ET |
King Pharmaceuticals Announces Date for Release of Second-Quarter 2005 Financial Results and Conference Call
|
|
Jul 20, 05
|
| 08:06 ET |
King Pharmaceuticals Reports the Lifting of the Consent Decree Affecting Its Rochester, Michigan Plant
|
|
Jun 10, 05
|
| 08:00 ET |
King Pharmaceuticals Announces Appointment of Eric J. Bruce as Corporate Head, Technical Operations
|
|
Jun 01, 05
|
| 08:04 ET |
King Pharmaceuticals Appoints Joseph Squicciarino Chief Financial Officer
|
|
May 16, 05
|
| 08:09 ET |
King Pharmaceuticals to Present at Banc of America Securities Healthcare Conference
|
|
May 09, 05
|
| 07:00 ET |
King Pharmaceuticals Reports First-Quarter 2005 Financial Results
|
|
May 05, 05
|
| 13:25 ET |
King Pharmaceuticals To Webcast Live Conference Call Following Release of First-Quarter 2005 Earnings
|
|
May 03, 05
|
| 08:41 ET |
King Pharmaceuticals Completes Wholesale Inventory Reductions
|
|
Apr 11, 05
|
| 08:07 ET |
King Pharmaceuticals To Webcast Live Conference Call
|
|
Mar 31, 05
|
| 08:11 ET |
King Pharmaceuticals To Webcast Live Conference Call
|
|
Mar 17, 05
|
| 16:11 ET |
King Pharmaceuticals Reports Fourth-Quarter and Year-End 2004 Financial Results
|
|
Mar 14, 05
|
| 17:47 ET |
King Pharmaceuticals Revises Scheduled Date for Release of Fourth Quarter 2004 Earnings
|
|
Feb 28, 05
|
| 07:02 ET |
King Pharmaceuticals Repositioned for Growth
|
|
| 06:45 ET |
King Pharmaceuticals Announces Date for Release of Fourth Quarter 2004 Earnings
|
|
Feb 22, 05
|
| 07:37 ET |
King Pharmaceuticals Completes Review Of Returns Reserve
|
|
Dec 08, 04
|
| 21:38 ET |
King Pharmaceuticals Provides Financial Update
|
|
Nov 15, 04
|
| 17:34 ET |
King Pharmaceuticals Provides Third-Quarter 2004 Financial Update
|
|
Nov 09, 04
|
| 17:25 ET |
King Pharmaceuticals to File 5-Day Extension for Form 10-Q
|
|
Nov 08, 04
|
| 08:17 ET |
King Pharmaceuticals Comments on Results of PEACE Trial
|
|
Oct 28, 04
|
| 07:45 ET |
King Pharmaceuticals Reports Preliminary Third-Quarter 2004 Financial Results
|
|
Oct 22, 04
|
| 16:45 ET |
King Pharmaceuticals to Webcast Live Conference Call Following Release of Third Quarter 2004 Earnings
|
|
Oct 12, 04
|
| 07:30 ET |
King Pharmaceuticals Announces Date for Release of Third-Quarter 2004 Financial Results
|
|
Sep 08, 04
|
| 15:27 ET |
King Pharmaceuticals Reiterates Commitment to Mylan Laboratories Transaction
|
|
Aug 13, 04
|
| 07:30 ET |
King Pharmaceuticals and Palatin Technologies Announce Strategic Alliance to Jointly Develop and Commercialize PT-141 as an Innovative Treatment for Sexual Dysfunction
|
|
Aug 05, 04
|
| 07:07 ET |
King Pharmaceuticals Reports Second-Quarter 2004 Financial Results
|
|
Aug 04, 04
|
| 21:44 ET |
King Pharmaceuticals Revises Scheduled Time for Webcast of Live Conference Call Following Release of Second-Quarter 2004 Earnings
|
|
Aug 02, 04
|
| 08:46 ET |
King Pharmaceuticals to Webcast Live Conference Call Following Release of Second-Quarter 2004 Earnings
|
|
Jul 16, 04
|
| 07:55 ET |
King Pharmaceuticals Announces Appointment of Brian A. Markison as President and CEO and as a Member of the Company's Board of Directors
|
|
Jul 15, 04
|
| 08:55 ET |
King Pharmaceuticals Announces Date for Release of Second-Quarter 2004 Financial Results
|
|
Jun 24, 04
|
| 21:36 ET |
King Pharmaceuticals Reports FDA Approval of Two Products as Bioequivalent for Levoxyl(R)
|
|
May 27, 04
|
| 16:30 ET |
King Pharmaceuticals to Establish Sales and Marketing Operations in New Jersey
|
|
May 18, 04
|
| 17:01 ET |
King Pharmaceuticals to Present at Banc Of America Securities Healthcare Conference
|
|
May 17, 04
|
| 18:25 ET |
King Pharmaceuticals Appoints Brian A. Markison Acting President and CEO and Elects Ted G. Wood Non-Executive Chairman
|
|
| 07:32 ET |
King Pharmaceuticals Announces Resignation of Jefferson J. Gregory
|
|
May 12, 04
|
| 07:31 ET |
King Pharmaceuticals Reports Receipt of Letter Regarding Status of Diazepam Product ANDA
|
|
May 10, 04
|
| 19:35 ET |
King Reiterates Commitment to Launch and Market Estrasorb(R)
|
|
May 06, 04
|
| 07:04 ET |
King Pharmaceuticals Reports First-Quarter 2004 Financial Results
|
|
May 03, 04
|
| 10:56 ET |
King Pharmaceuticals to Webcast Live Conference Call Following Release of First-Quarter 2004 Earnings
|
|
Apr 15, 04
|
| 09:30 ET |
King Pharmaceuticals Announces Date For Release Of First-Quarter 2004 Financial Results
|
|
Mar 12, 04
|
| 06:30 ET |
King Pharmaceuticals Responds to Letter to ANDA Applicants for Skelaxin(R)
|
|
Mar 05, 04
|
| 07:31 ET |
King Pharmaceuticals Initiates Phase II Clinical Trial for Extended Release Formulation of Sonata(R)
|
|
Feb 19, 04
|
| 06:32 ET |
King Pharmaceuticals Reports Fourth-Quarter and Year-End 2003 Financial Results
|
|
Feb 18, 04
|
| 08:31 ET |
King Pharmaceuticals to Webcast Live Conference Call Following Release of Fourth-Quarter and Year-End 2003 Earnings
|
|
Feb 09, 04
|
| 12:29 ET |
King Pharmaceuticals Announces Date for Release of Fourth Quarter 2003 Earnings
|
|
Feb 03, 04
|
| 07:48 ET |
King Pharmaceuticals' Investigational New Drug Application for an Extended Release Formulation of Sonata(R) Now Active
|
|
Feb 02, 04
|
| 07:42 ET |
King Appoints Brian A. Markison to Newly Created COO Position and Harsha Murthy to Head Strategic Planning and Business Development
|
|
Jan 30, 04
|
| 11:55 ET |
King Pharmaceuticals to Present At Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
|
|
Jan 29, 04
|
| 07:31 ET |
King Pharmaceuticals Reports Publication of Binodenoson Phase II Clinical Data in AHA Journal Circulation
|
|
Jan 27, 04
|
| 08:11 ET |
King Pharmaceuticals Announces Issuance of Additional U.S. Patent For Skelaxin(R)
|
|
Jan 13, 04
|
| 07:31 ET |
King Pharmaceuticals Completes Initial Dosing in Phase I Trial Involving Treatment for Chronic Diabetic Neuropathic Foot Ulcers
|
|
Jan 09, 04
|
| 15:41 ET |
King Pharmaceuticals to Present at JPMorgan Annual Healthcare Conference
|
|
Dec 11, 03
|
| 07:31 ET |
King Pharmaceutical's Commences Phase I Clinical Trial for Neuropathic Pain Drug
|
|
Dec 05, 03
|
| 07:00 ET |
King Pharmaceuticals Commences Phase III Clinical Trial Involving Binodenoson
|
|
Nov 14, 03
|
| 07:34 ET |
King Pharmaceuticals Reports Receipt Of Subpoena From OIG
|
|
Nov 03, 03
|
| 08:05 ET |
King Pharmaceuticals Announces Completion of Patient Enrollment in Altace(R) Pediatric Clinical Trial
|
|
Oct 30, 03
|
| 08:01 ET |
King Pharmaceuticals Announces Receipt Of FDA Approvable Letter for Intal(R) HFA
|
|
Oct 28, 03
|
| 07:02 ET |
King Pharmaceuticals Reports Third-Quarter 2003 Financial Results
|
|
Oct 27, 03
|
| 07:11 ET |
King Pharmaceutical's Investigational New Drug Application For Neuropathic Pain Drug Now Active
|
|
Oct 24, 03
|
| 08:02 ET |
King Pharmaceuticals to Present Three Abstracts on Binodenoson at the American Heart Association Meeting
|
|
Oct 17, 03
|
| 08:00 ET |
King Pharmaceuticals Announces Date for Release of Third Quarter 2003 Earnings And Webcast of Live Conference Call Following Release
|
|
Sep 04, 03
|
| 08:30 ET |
King to Present Five Abstracts on Binodenoson at the American Society of Nuclear Cardiology Meeting
|
|
Sep 03, 03
|
| 08:15 ET |
King Pharmaceuticals and Wyeth Report HOPE-TOO Study Shows Sustained Effect Of Altace(R) in Reducing Risk of Cardiovascular Disease
|
|
Aug 26, 03
|
| 07:30 ET |
King Pharmaceuticals Announces Appointment of Ted G. Wood to Board Of Directors
|
|
Jul 29, 03
|
| 06:55 ET |
King Pharmaceuticals Reports Second-Quarter 2003 Financial Results
|
|
| 06:39 ET |
King Pharmaceuticals Announces the Completion of Audit Committee's Independent Review and King's Filing of 2002 Form 10-K and First-Quarter 2003 Form 10-Q
|
|
Jul 23, 03
|
| 08:14 ET |
King Pharmaceuticals to Webcast Live Conference Call Following Release of Second-Quarter 2003 Earnings
|
|
Jul 18, 03
|
| 08:00 ET |
King Pharmaceuticals Announces Date for Release of Second-Quarter 2003 Financial Results
|
|
Jun 25, 03
|
| 07:32 ET |
King Pharmaceuticals Reports Receipt of Second Notice of Paragraph IV Certification Pertaining to Levoxyl(R)
|
|
Jun 20, 03
|
| 07:30 ET |
King Pharmaceuticals Receives FDA Approval for ATROPEN(R)
|
|
Jun 13, 03
|
| 07:30 ET |
King Pharmaceuticals Completes Acquisition of Primary Care Business From Elan
|
|
May 20, 03
|
| 07:03 ET |
King Pharmaceuticals Reaches Revised Agreement to Proceed with Acquisition of Elan's Primary Care Business
|
|
May 19, 03
|
| 07:35 ET |
King Pharmaceuticals and Skyepharma Announce Licensing Agreement to Develop Modified-Release Formulation of Altace(R)
|
|
May 15, 03
|
| 17:44 ET |
King Pharmaceuticals Files 5-Day Extension for Form 10-Q
|
|
May 08, 03
|
| 17:01 ET |
King Pharmaceuticals Reaffirms Intent Not to Proceed With Acquisition of Elan's Primary Care Business
|
|
May 06, 03
|
| 06:30 ET |
King Pharmaceuticals Reports Solid Growth for First-Quarter 2003
|
|
May 01, 03
|
| 07:32 ET |
King Pharmaceuticals Reports Receipt From Mylan Pharmaceuticals of Notice of Paragraph IV Certification Pertaining to Levoxyl(R)
|
|
Apr 29, 03
|
| 10:45 ET |
King Pharmaceuticals Announces Issuance of U.S. Patent for Levoxyl(R)
|
|
| 08:06 ET |
King Pharmaceuticals to Webcast Live Conference Call Following Release of First-Quarter 2003 Earnings
|
|
Apr 25, 03
|
| 07:30 ET |
King Pharmaceuticals Provides First-Quarter 2003 Preview
|
|
Apr 15, 03
|
| 17:56 ET |
King Pharmaceuticals Releases 2002 Unaudited Consolidated Financial Statements And Other Information Typically Included in Form 10-K
|
|
Apr 02, 03
|
| 07:32 ET |
King Pharmaceuticals Does Not Plan To Proceed With Acquisition of Elan's Primary Care Business
|
|
Mar 31, 03
|
| 17:30 ET |
15-Day Extension for Form 10-K Filed by King Pharmaceuticals
|
|
Mar 14, 03
|
| 10:02 ET |
King Pharmaceuticals Clarifies Inaccurate Statements in Certain Newswire Stories This Morning
|
|
| 07:00 ET |
King Pharmaceuticals Reports Receipt of FTC Letter Relating to Elan's Product Skelaxin(R)
|
|
Mar 11, 03
|
| 06:30 ET |
King Pharmaceuticals Reports Receipt of SEC Document Request, Pledges Full and Complete Cooperation
|
|
Feb 28, 03
|
| 08:30 ET |
King Pharmaceuticals Reports Publication of Favorable Altace(R) Data from Hope Trial Relating to Prevention of Heart Failure
|
|
Feb 18, 03
|
| 07:03 ET |
King Pharmaceuticals Reports Fourth Quarter 2002 Net Earnings Growth Of 32 Percent to $98.1 Million, Diluted EPS Increases 32 Percent to 41 Cents, Excluding Special Items
|
 |
Feb 12, 03
|
| 08:14 ET |
King Pharmaceuticals to Webcast Live Conference Call Following Release of Fourth Quarter and Year-End 2002 Earnings
|
|
Feb 05, 03
|
| 16:15 ET |
King Pharmaceuticals Reports Receipt From Cobalt Pharmaceuticals, Inc. Of Notice of Paragraph IV Certification Pertaining to Altace(R) (ramipril)
|
|
Feb 03, 03
|
| 18:20 ET |
King Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
|
|
Jan 31, 03
|
| 07:00 ET |
King Pharmaceuticals Provides Increased Earnings and Revenue Projections for 2003
|
|
Jan 30, 03
|
| 11:58 ET |
King Pharmaceuticals to Webcast Live Conference Call Today To Discuss Acquisition of Primary Care Business Unit From Elan
|
|
| 05:59 ET |
King Pharmaceuticals Acquires Primary Care Business Unit From Elan
|
|
Jan 29, 03
|
| 21:09 ET |
King Pharmaceuticals Provides Fourth-Quarter and Year-End 2002 Revenue and Earnings Preview
|
|
Jan 09, 03
|
| 07:31 ET |
King Pharmaceuticals Completes Acquisition of Meridian Medical Technologies
|
|
Jan 08, 03
|
| 18:39 ET |
King Pharmaceuticals Previously Announced Planned Acquisition of Meridian Medical Technologies Approved by Meridian Shareholders
|
|
| 16:17 ET |
King Pharmaceuticals Reiterates Confidence in Strength of Altace(R) (Ramipril) Patents
|
|
Jan 02, 03
|
| 18:40 ET |
King Pharmaceuticals to Present At JPMorgan H&Q 21st Annual Healthcare Conference
|
|
Dec 31, 02
|
| 07:00 ET |
King Pharmaceuticals Acquires Rights to Intal(R), Tilade(R), and Synercid(R) From Aventis
|
|
Dec 26, 02
|
| 07:39 ET |
FDA Publishes Federal Register Notice Declaring Unapproved Trimethobenzamide Hydrochloride Capsules Unlawful
|
|
Dec 19, 02
|
| 07:30 ET |
Recently Reported ALLHAT Trial Does Not Address Benefits of Altace; Altace Benefits Proven in Landmark HOPE Trial
|
|
Dec 12, 02
|
| 09:42 ET |
King Pharmaceuticals Reports Favorable Sequential Estrogen-Progestin Replacement Therapy Study Published by the American College of Obstetricians And Gynecologists
|
|
Dec 10, 02
|
| 17:57 ET |
King Pharmaceuticals Reports Meridian Medical Technologies' Announcement of Financial Results for First Quarter of Fiscal 2003
|
|
Nov 21, 02
|
| 09:51 ET |
King Pharmaceuticals Reports Favorable Altace(R) Trial Published in Journal of American Medical Association
|
|
Nov 08, 02
|
| 16:30 ET |
King Pharmaceuticals to Present at SG Cowan Global Health Care Conference
|
|
| 07:03 ET |
King Pharmaceuticals Reports Publication Of New Study Involving Altace(R)
|
|
Nov 05, 02
|
| 12:49 ET |
King Pharmaceuticals Refutes False Report Concerning Forecasts
|
|
Nov 01, 02
|
| 08:00 ET |
King Pharmaceuticals to Present at CIBC World Markets Health Care Conference
|
|
Oct 28, 02
|
| 07:03 ET |
King Pharmaceuticals Reports Solid Revenue Growth for Third Quarter 2002 of 37% to $315.7 Million and Net Earnings Growth of 31% to $84.7 Million, Excluding Special Charges
|
|
Oct 22, 02
|
| 09:06 ET |
King Pharmaceuticals to Webcast Live Conference Call Following Release of Third Quarter 2002 Earnings
|
|
Oct 21, 02
|
| 06:06 ET |
King Pharmaceuticals to Acquire Meridian Medical Technologies
|
|
Oct 10, 02
|
| 07:02 ET |
King Pharmaceuticals Updates Expeditious Progress of Pending Patent Protection for Levoxyl(R)
|
|
Oct 09, 02
|
| 08:01 ET |
King Pharmaceuticals Announces Date for Release of Third Quarter 2002 Earnings
|
|
Oct 08, 02
|
| 07:01 ET |
King Pharmaceuticals Announces Exclusive License for Tetrac
|
|
| 06:00 ET |
King Pharmaceuticals Announces Appointment Of James R. Lattanzi to Board of Directors
|
|
Jul 29, 02
|
| 06:30 ET |
King Pharmaceuticals Reports Solid Revenue Growth for Second Quarter 2002 of 37 Percent to $282.5 Million and Net Earnings Growth of 36 Percent to $77.1 Million, Excluding Special Charges
|
|
Jul 23, 02
|
| 08:11 ET |
King Pharmaceuticals to Webcast Live Conference Call Following Release of Second Quarter 2002 Earnings
|
|
Jul 11, 02
|
| 07:33 ET |
King Pharmaceuticals Announces Date For Release Of Second Quarter 2002 Earnings
|
|
Jun 27, 02
|
| 07:02 ET |
King Pharmaceuticals Provides 2003 Financial Guidance
|
|
Jun 24, 02
|
| 07:31 ET |
King Pharmaceuticals Reiterates Pending Patent Protection For Its FDA-Approved New Formulation of Levoxyl(R)
|
|
Jun 17, 02
|
| 08:32 ET |
King Pharmaceuticals Named No. 1 in Profitability
|
|
Jun 06, 02
|
| 08:02 ET |
King Pharmaceuticals Named to List of Top 100 'Hot Growth Companies'
|
|
Jun 03, 02
|
| 16:15 ET |
King Pharmaceuticals to Present at The UBS Warburg Global Specialty Pharmaceuticals Conference
|
|
May 29, 02
|
| 08:01 ET |
King Pharmaceuticals Completes Acquisition of Ortho-Prefest(R)
|
|
May 21, 02
|
| 13:02 ET |
King Pharmaceuticals Reports That Altace(R) is Now the No. 1 ACE Inhibitor Among Endocrinologists and Cardiologists Based on New Prescription Market Share
|
|
May 17, 02
|
| 08:00 ET |
King Pharmaceuticals Reports Termination of Blind Trusts By John M. Gregory, Chairman, Joseph R. Gregory, Vice Chairman, And Jefferson J. Gregory, Chief Executive Officer
|
|
May 14, 02
|
| 13:30 ET |
King Pharmaceuticals Reports That Altace(R) Achieves No. 1 New Prescription Market Share Among Cardiologists for ACE Inhibitors
|
|
| 08:03 ET |
King Pharmaceuticals Announces Plan to Repurchase Common Stock
|
|
| 08:03 ET |
King Pharmaceuticals Announces Plan to Repurchase Common Stock
|
|
Apr 29, 02
|
| 06:45 ET |
King Pharmaceuticals Reports Strong Earnings and Revenue Growth For First Quarter 2002, With Diluted EPS Growth of 53% to $0.29
|
|
| 06:30 ET |
King Pharmaceuticals Acquires Ortho-Prefest(R) From Ortho-McNeil Pharmaceutical
|
|
Apr 24, 02
|
| 23:21 ET |
Novavax Reports Status of NDA for Estrasorb(TM)
|
|
Apr 18, 02
|
| 08:30 ET |
King Pharmaceuticals to Webcast Live Conference Call Following Release of First Quarter 2002 Earnings
|
|
Apr 09, 02
|
| 08:00 ET |
King Pharmaceuticals Announces Date For Release of First Quarter 2002 Earnings
|
|
Apr 02, 02
|
| 17:09 ET |
King Pharmaceuticals to Present at Banc of America Securities Healthcare Conference
|
|
Mar 27, 02
|
| 06:30 ET |
King Pharmaceuticals Announces Launch of Direct-to-Consumer Marketing Campaign for Altace(R)
|
|
Feb 19, 02
|
| 07:02 ET |
King Pharmaceuticals Reports Fourth Quarter 2001 Net Earnings Growth Of 35 Percent to $74.1 Million, Diluted EPS of 31 Cents (Up 29 Percent), Excluding Special Charges
|
|
Feb 14, 02
|
| 15:12 ET |
King Pharmaceuticals Responds to Incorrect Report of Sales Of Stock By Affiliates
|
|
Feb 07, 02
|
| 06:30 ET |
King Pharmaceuticals Launches Tigan(R) Capsules And Files U.S. Patent Application
|
|
Feb 04, 02
|
| 16:15 ET |
King Pharmaceuticals to Webcast Live Conference Call Following Release of Fourth Quarter and Year-End 2001 Earnings
|
|
| 07:03 ET |
King Pharmaceuticals Responds to Recent Unjustified Share Price Decline
|
|
Feb 01, 02
|
| 20:05 ET |
King Pharmaceuticals to Present at Merrill Lynch & Co., Inc. Global Pharmaceutical, Biotechnology & Medical Device Conference
|
|
Jan 23, 02
|
| 08:00 ET |
King Pharmaceuticals Announces Date For Release Of Fourth Quarter and Year-End 2001 Earnings
|
|
Jan 03, 02
|
| 16:19 ET |
King Pharmaceuticals to Present at JPMorgan H&Q 20th Annual Healthcare Conference
|
|
Dec 21, 01
|
| 17:23 ET |
King Pharmaceuticals Will Withdraw NDA for Theelin(R)
|
|
Dec 17, 01
|
| 07:01 ET |
King Pharmaceuticals Provides 2002 Quarterly Financial Guidance
|
|
Dec 14, 01
|
| 11:45 ET |
King Pharmaceuticals Announces FDA Approval of Tigan(R) Capsules NDA
|
|
Dec 10, 01
|
| 08:15 ET |
King Pharmaceuticals Sets Tender Offer Pricing for Its Outstanding 10 3/4% Senior Subordinated Notes
|
|
| 08:03 ET |
King Pharmaceuticals Announces Exercise of Over-Allotment Options in Recent Public Equity Offering and Private Debt Offering
|
|
Nov 28, 01
|
| 08:30 ET |
King Pharmaceuticals Announces Receipt of Requisite Consents From Holders Of Its Outstanding 10 3/4% Senior Subordinated Notes
|
|
Nov 09, 01
|
| 08:00 ET |
King Pharmaceuticals Announces Cash Tender Offer for Outstanding 10 3/4% Senior Subordinated Notes
|
|
Nov 08, 01
|
| 08:15 ET |
King Pharmaceuticals Receives Proceeds From Sale of Stock and Convertible Debentures
|
|
Nov 02, 01
|
| 17:40 ET |
King Pharmaceuticals To Present At CIBC World Markets Health Care Conference
|
|
| 08:30 ET |
King Pharmaceuticals Announces Pricing of Public Common Stock Offering and Private Debt Offering
|
|
Oct 31, 01
|
| 08:00 ET |
King Pharmaceuticals to Present at CIBC World Markets Health Care Conference
|
|
Oct 29, 01
|
| 13:19 ET |
King Pharmaceuticals Announces Jack Nicklaus As Spokesperson For Altace(R)
|
|
| 07:01 ET |
King Pharmaceuticals Reports Solid Revenue Growth for Third Quarter 2001 of 39% to $230.1 Million and Diluted Earnings Per Share Growth of 33% to $0.28, Excluding Special Charges
|
|
Oct 23, 01
|
| 16:24 ET |
King Pharmaceuticals, Inc. Announces Public Common Stock Offering and Private Debt Offering
|
|
Oct 16, 01
|
| 07:01 ET |
John M. Gregory, Chairman of King Pharmaceuticals, Announces That Jefferson J. Gregory, President of King, Will Become Also Chief Executive Officer of King, Effective January 1, 2002
|
|
Oct 15, 01
|
| 08:30 ET |
King Pharmaceuticals to Webcast Live Conference Call Following Release of Third Quarter 2001 Earnings
|
|
Oct 02, 01
|
| 08:01 ET |
King Pharmaceuticals Hires Cardiovascular Sales Force
|
|
Oct 01, 01
|
| 08:30 ET |
King Pharmaceuticals Announces Date for Release of Third Quarter 2001 Earnings
|
|
Sep 21, 01
|
| 17:00 ET |
King Pharmaceuticals to Present at Raymond James Healthcare Conference
|
|
Sep 05, 01
|
| 07:30 ET |
FDA Accepts for Review New Drug Application for Estrasorb(TM), a Topical Estrogen Replacement Therapy Licensed to King Pharmaceuticals
|
|
Aug 09, 01
|
| 07:45 ET |
King Pharmaceuticals Acquires U.S. Rights to Corzide(R), Corgard(R), Delestrogen(R), and Florinef(R) from Bristol-Myers Squibb Company
|
|
Jul 23, 01
|
| 07:01 ET |
King Pharmaceuticals Reports Strong Growth for Second Quarter 2001 Net Earnings of 77 Percent to $56.8 Million on Revenues of $206.5 Million, Excluding Special Charges During the Prior Year
|
|
Jul 20, 01
|
| 08:01 ET |
King Pharmaceuticals Announces Distribution of Four for Three Stock Split
|
|
Jul 12, 01
|
| 16:18 ET |
King Pharmaceuticals To Webcast Live Conference Call Following Release of Second Quarter 2001 Earnings
|
|
Jul 03, 01
|
| 16:32 ET |
King Pharmaceuticals Files $1.5 Billion Universal Shelf Registration Statement
|
|
Jun 29, 01
|
| 14:29 ET |
Novavax Submits New Drug Application for ESTRASORB(TM), A Topical Estrogen Replacement Therapy Licensed to King
|
|
Jun 21, 01
|
| 16:15 ET |
King Pharmaceuticals Announces Date for Release Of Second Quarter 2001 Earnings
|
|
| 09:36 ET |
King Pharmaceuticals Announces Four For Three Stock Split
|
|
Jun 07, 01
|
| 16:57 ET |
King Pharmaceuticals Reports National Institutes of Health Release
|
|
Jun 01, 01
|
| 07:30 ET |
King Pharmaceuticals Increases Revenue and Earnings Projections for 2002
|
|
May 25, 01
|
| 14:45 ET |
King Pharmaceuticals Receives Approval for Levoxyl(R) NDA From FDA
|
|
May 22, 01
|
| 07:00 ET |
King Pharmaceuticals Increases Revenue and Earnings Projections For Second Quarter and Year-End 2001
|
|
May 18, 01
|
| 08:00 ET |
King Pharmaceuticals to Present at UBS Warburg Global Specialty Pharmaceuticals Conference
|
|
Apr 30, 01
|
| 07:01 ET |
King Pharmaceuticals Reports Strong Earnings Growth for First Quarter 2001
|
|
Apr 27, 01
|
| 08:30 ET |
King Pharmaceuticals to Webcast Live Conference Call Following Release of First Quarter 2001 Earnings
|
|
Apr 17, 01
|
| 16:15 ET |
King Pharmaceuticals to Webcast Live Conference Call Following Release of First Quarter 2001 Earnings
|
|
Apr 12, 01
|
| 07:31 ET |
King Pharmaceuticals Expects First Quarter Earnings to Exceed Expectations
|
|
Apr 09, 01
|
| 08:04 ET |
King Pharmaceuticals Expects Gross Profit to Benefit From Thrombin Contract Expiration
|
|
Apr 02, 01
|
| 08:31 ET |
King Pharmaceuticals Announces Date for Release Of First Quarter 2001 Earnings
|
|
Mar 22, 01
|
| 16:31 ET |
King Pharmaceuticals to Present at Banc of America Securities Healthcare Conference
|
|
Mar 15, 01
|
| 09:10 ET |
King Pharmaceuticals Reports Plans for Worldwide Study Involving Altace(R)
|
|
Mar 05, 01
|
| 16:15 ET |
King Pharmaceuticals to Present at Salomon Smith Barney 1st Annual Specialty Pharmaceuticals Conference
|
|
Feb 21, 01
|
| 08:04 ET |
King Pharmaceuticals Reports McMaster Release Pertaining to Secure Study Involving Altace(R)
|
|
Feb 20, 01
|
| 17:04 ET |
King Pharmaceuticals Reports Fourth Quarter 2000 Net Earnings Growth Of 114 Percent to $54.9 Million, Diluted EPS of 32 Cents (Up 100 Percent), Excluding Special Charges
|
|
Feb 14, 01
|
| 08:31 ET |
King Pharmaceuticals to Webcast Live Conference Call Following Release of Fourth Quarter and Year-End 2000 Earnings
|
|
Feb 12, 01
|
| 16:15 ET |
King Pharmaceuticals to Webcast Live Conference Call Following Release of Fourth Quarter and Year-End 2000 Earnings
|
|
Jan 25, 01
|
| 08:30 ET |
King Pharmaceuticals to Present at U. S. Bancorp Piper Jaffray Healthcare Conference
|
|
Jan 19, 01
|
| 12:37 ET |
King Pharmaceuticals Reports Ratings Upgrade by Moody's Investors Services
|
|
Jan 17, 01
|
| 17:44 ET |
King Pharmaceuticals Announces Date for Release Of Fourth Quarter and Year-End 2000 Earnings
|
|
Jan 12, 01
|
| 07:00 ET |
King Pharmaceuticals Not Interested In Acquiring Carter-Wallace Pharmaceutical Business
|
|
Jan 08, 01
|
| 08:03 ET |
King Pharmaceuticals Announces Exclusive License for Estrasorb(TM) with Novavax
|
|
Jan 05, 01
|
| 09:58 ET |
King Pharmaceuticals to Present at J. P. Morgan H&Q Annual Healthcare Conference
|
|
Dec 20, 00
|
| 08:01 ET |
King Pharmaceuticals Announces Exclusive License For HPV Vaccines With Novavax
|
|
Dec 11, 00
|
| 08:15 ET |
King Pharmaceuticals Announces Appointment Of R. Charles Moyer to Board of Directors
|
|
Dec 07, 00
|
| 08:01 ET |
King Pharmaceuticals has Purchased and Will Redeem Senior Subordinated Notes Totaling $53.6 Million
|
|
Dec 06, 00
|
| 07:30 ET |
King Pharmaceuticals Announces Creation of Blind Trusts by Certain Affiliates
|
|
Nov 08, 00
|
| 19:15 ET |
King Pharmaceuticals Appoints Jefferson J. Gregory As President of Jones Pharma
|
|
| 09:00 ET |
King Pharmaceuticals Presents At Prudential Vector Healthcare Conference
|
|
Nov 03, 00
|
| 06:00 ET |
Updated: King Pharmaceuticals Reports Third Quarter 2000 EPS of $0.27 Excluding Special Charges
|
|
Nov 02, 00
|
| 22:12 ET |
King Pharmaceuticals Reports Third Quarter 2000 EPS of $0.27 Excluding Special Charges
|
|
Nov 01, 00
|
| 14:11 ET |
King Pharmaceuticals Reports Canadian Institutes of Health Research Release Announcing Funding of Clinical Trial Involving Altace(R)
|
|
Oct 20, 00
|
| 14:47 ET |
King Pharmaceuticals Receives Proceeds From Sale of Stock
|
|
Oct 17, 00
|
| 09:08 ET |
King Pharmaceuticals Announces Sale of Stock
|
|
Oct 16, 00
|
| 07:31 ET |
King Pharmaceuticals Reports National Institutes of Health Release
|
|
Oct 10, 00
|
| 08:02 ET |
King Pharmaceuticals to Receive $50 Million Payment From American Home Products Under Co-promotion Arrangement for Altace(R)
|
|
Oct 05, 00
|
| 16:23 ET |
ALTACE(R) (ramipril) Receives New Indication to Reduce Risk Of Stroke, Heart Attack and Death From Cardiovascular Causes
|
|
Sep 28, 00
|
| 06:59 ET |
S&P 500 Index Adds King Pharmaceuticals
|
|
Sep 27, 00
|
| 20:51 ET |
King Pharmaceuticals Announces Expected Merger and Other Restructuring Charges
|
|
Sep 12, 00
|
| 08:08 ET |
King Pharmaceuticals Announces Management Appointments Following Merger With Jones Pharma
|
|
Aug 31, 00
|
| 13:09 ET |
King Pharmaceuticals Completes Previously Announced Merger With Jones Pharma
|
|
| 11:04 ET |
Shareholders Approve Merger of King Pharmaceuticals And Jones Pharma Incorporated
|
|
Aug 03, 00
|
| 08:01 ET |
King Pharmaceuticals and Jones Pharma Incorporated Schedule Special Shareholder Meetings for August 31, 2000
|
|
Jul 24, 00
|
| 05:00 ET |
King Pharmaceuticals Reports Solid Growth In Second Quarter Revenue and Earnings
|
|
Jul 13, 00
|
| 11:58 ET |
King Pharmaceuticals and Jones Pharma Incorporated Announce Merger
|
|
Jun 23, 00
|
| 09:50 ET |
American Home Products and King Pharmaceuticals Finalize Co-Promotion Arrangement For Altace(R)
|
|
Jun 22, 00
|
| 08:01 ET |
King Pharmaceuticals Announces Distribution of Three For Two Stock Split
|
|
Jun 12, 00
|
| 06:59 ET |
Parkedale Pharmaceuticals Meets with FDA to Discuss Progress of Fluogen(R) Compliance Program
|
|
Jun 02, 00
|
| 07:45 ET |
King Pharmaceuticals Announces Three for Two Stock Split
|
|
May 22, 00
|
| 12:00 ET |
King Pharmaceuticals to Begin Trading on the New York Stock Exchange Under the Symbol 'KG'
|
|
May 09, 00
|
| 08:01 ET |
King Pharmaceuticals to List on the New York Stock Exchange
|
|
May 02, 00
|
| 05:30 ET |
King Pharmaceuticals Announces FDA Advisory Committee's Recommendation for Approval of Potential New Indications for ALTACE(R)
|
|
Apr 25, 00
|
| 15:31 ET |
King Pharmaceuticals Receives Proceeds From Sale of Stock
|
|
Apr 19, 00
|
| 01:22 ET |
King Pharmaceuticals Announces Sale of Stock
|
|
Apr 13, 00
|
| 15:35 ET |
Parkedale Pharmaceuticals Resumes Production of Fluogen(R)
|
|
Mar 28, 00
|
| 17:01 ET |
Parkedale Pharmaceuticals Receives Correspondence From FDA Allowing Continued Distribution of Aplisol(R)
|
|
Mar 23, 00
|
| 15:41 ET |
FDA Approves Release of Aplisol(R) by Parkedale Pharmaceuticals
|
|
Mar 21, 00
|
| 08:31 ET |
Supplemental New Drug Application for Altace(R) Accepted for Review by FDA
|
|
Mar 17, 00
|
| 08:30 ET |
King Pharmaceuticals Announces License Agreement For Menest(R) In Latin America
|
|
Mar 12, 00
|
| 22:14 ET |
Parkedale Pharmaceuticals Receives FDA Notification Related to Fluogen(R)
|
|
Mar 10, 00
|
| 12:01 ET |
King Pharmaceuticals Appoints Executive Vice President Of Clinical Research And Development
|
|
| 08:29 ET |
FDA Advisory Committee To Review Supplemental New Drug Application For Altace(R)
|
|
Feb 25, 00
|
| 17:45 ET |
King Pharmaceuticals Completes Previously Announced Merger With Medco Research
|
|
| 11:10 ET |
Medco Research Shareholders Approve Merger With King Pharmaceuticals
|
|
Feb 24, 00
|
| 19:39 ET |
King Pharmaceuticals Reports Favorable Ruling By Chancery Court on Planned Merger With Medco Research
|
|
Feb 16, 00
|
| 06:30 ET |
King Pharmaceuticals Reports Solid Revenue and Earnings Growth For 1999 Fourth Quarter and Year-End
|
|
Feb 11, 00
|
| 16:14 ET |
King Pharmaceuticals Affirms Existing Terms Of Planned Merger With Medco Research
|
|
Feb 10, 00
|
| 09:48 ET |
King Pharmaceuticals Reports Response By Medco Research to Chancery Court Ruling
|
|
Feb 04, 00
|
| 13:52 ET |
Merck-Medco Adds Altace(R) and Lorabid(R) to National Formulary
|
|
Jan 21, 00
|
| 17:13 ET |
King Pharmaceuticals Files $350 Million Universal Shelf Registration Statement
|
|
Jan 19, 00
|
| 08:31 ET |
King Pharmaceuticals Submits Supplemental New Drug Application for Altace(R)
|
|
Dec 01, 99
|
| 07:02 ET |
King Pharmaceuticals Announces Acquisition of Medco Research
|
|
Nov 12, 99
|
| 08:01 ET |
King Pharmaceuticals Announces Distribution of Three for Two Stock Split
|
|
Nov 10, 99
|
| 17:05 ET |
King Pharmaceuticals Announces the New England Journal of Medicine's Early Release of Hope Study Results
|
|
Nov 01, 99
|
| 08:31 ET |
King Pharmaceuticals Expresses ConfidenceIn Projected Performance
|
|
Oct 25, 99
|
| 06:20 ET |
King Pharmaceuticals Reports Strong Third Quarter Earnings
|
|
Oct 22, 99
|
| 07:29 ET |
Parkedale Pharmaceuticals Licenses Novavax Technology For Improvement of Influenza Vaccine
|
|
Oct 21, 99
|
| 07:31 ET |
King Pharmaceuticals and Adams Laboratories Announce Copromotion Agreement
|
|
Oct 04, 99
|
| 07:30 ET |
King Pharmaceuticals Announces Three for Two Stock Split
|
|
Sep 01, 99
|
| 08:30 ET |
Monarch Pharmaceuticals Reports: Study Demonstrates Dramatic Results for Patients Worldwide
|
|
Aug 19, 99
|
| 09:47 ET |
King Pharmaceuticals Completes Previously Announced Acquisition of U.S. Rights To Lorabid(R) From Lilly
|
|
Aug 06, 99
|
| 08:56 ET |
King Pharmaceuticals Commences Shipping of Fluogen(R)
|
|
Aug 02, 99
|
| 07:30 ET |
King Pharmaceuticals to Acquire U.S. Rights to Lorabid(R) from Lilly
|
|
Jul 29, 99
|
| 10:45 ET |
Monarch Pharmaceuticals Appoints Vice President of Physician Sales
|
|
Jul 26, 99
|
| 06:59 ET |
King Pharmaceuticals Reports Solid Second Quarter Revenue and Earnings Growth
|
|
Jul 09, 99
|
| 10:44 ET |
Russell 2000 Index Adds King Pharmaceuticals
|
|
Jul 06, 99
|
| 08:27 ET |
King Pharmaceuticals Expects Second Quarter Earnings to Exceed Expectations
|
|
Jul 01, 99
|
| 09:14 ET |
Copromotion of King Pharmaceuticals' Altace(R) Commenced by Medeva Pharmaceuticals
|
|
Jun 15, 99
|
| 16:03 ET |
King Pharmaceuticals and Falcon Pharmaceuticals Enter Into Supply Agreement for Generic Cortisporin(R) Otic Products
|
|
Jun 08, 99
|
| 11:24 ET |
King Pharmaceuticals Announces Extension of Exchange Offer
|
|
May 12, 99
|
| 08:29 ET |
King Pharmaceuticals Announces HOPE Study Release
|
|
May 10, 99
|
| 07:29 ET |
King Pharmaceuticals and Medeva Pharmaceuticals Announce Copromotion Agreement
|
|
Apr 26, 99
|
| 06:59 ET |
King Pharmaceuticals Reports Strong First Quarter Earnings
|
|
Mar 04, 99
|
| 08:12 ET |
King Pharmaceuticals Completes Private Offering of $150MM Senior Subordinated Notes
|
|
Feb 26, 99
|
| 08:30 ET |
King Pharmaceuticals Announces Pre-Season Purchase Orders for Fluogen(R)
|
|
Feb 16, 99
|
| 07:01 ET |
King Pharmaceuticals Reports a 248% Increase In Fourth Quarter Earnings, Excluding One-Time Charge
|
|
Feb 08, 99
|
| 08:22 ET |
King Pharmaceuticals To Commence Private Offering Of $200MM Senior Subordinated Notes
|
|
Jan 15, 99
|
| 07:53 ET |
King Pharmaceuticals Hires Former Altace(R) Product Manager
|
|
Dec 22, 98
|
| 09:13 ET |
King Pharmaceuticals, Inc. Completes Acquisition Previously Announced
|
|
Dec 18, 98
|
| 07:30 ET |
King Pharmaceuticals and Hoechst Marion Roussel Sign an Agreement for One Of The Largest Single Product Transactions in Emerging Pharmaceutical Sector
|
|
Dec 17, 98
|
| 20:40 ET |
King Pharmaceuticals and Hoechst Marion Roussel Sign an Agreement for One Of The Largest Single Product Transactions in Emerging Pharmaceutical Sector
|
|
Oct 27, 98
|
| 09:02 ET |
King Pharmaceuticals Reports Record Third Quarter Earnings
|
|
Oct 14, 98
|
| 09:03 ET |
King Pharmaceuticals Expects Third Quarter Earnings To Exceed Expectations
|
|
Jul 23, 98
|
| 16:57 ET |
King Pharmaceuticals Reports Second Quarter Earnings Gain
|
|
Jul 08, 98
|
| 19:58 ET |
King Pharmaceuticals, Inc. Acquires Estrogen Product from SmithKline Beecham Pharmaceuticals, Inc.
|
|
